Dr. Joseph Patrick Erinjeri, MD, PhD

Dr. Erinjeri practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Erinjeri's NPI, 1437289048, was assigned on March 6, 2007. Dr. Erinjeri graduated from Washington University School of Medicine in 2002. Dr. Erinjeri holds New York license 243403.

Dr. Erinjeri's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Erinjeri's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Monmouth. Dmand AI also links Dr. Erinjeri to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Erinjeri practices. Vendor and product names are available with a free account.

Vascular and interventional radiology is Dr. Erinjeri's primary specialty in the NPI Registry, under taxonomy code 2085R0204X. Dr. Erinjeri is licensed in New York.

CMS data shows 479 Medicare services from Dr. Erinjeri across 16 procedure codes in 2024, for 243 Medicare patients. Medicare paid $40,896 for them.

CMS counts 243 Medicare patients who saw Dr. Erinjeri in 2024. The largest group is 65 to 74, with 113 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 16% are also on Medicaid. Their average risk score is 2.71, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Erinjeri's median patient age at 71, with 58% women.

In 2024, Dr. Erinjeri wrote 11 Medicare Part D claims. Every claim was for a generic drug. They cover 1 drug, with $19 in total drug cost. In 2018, CMS named 13 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Erinjeri for performance year 2024, reported as part of a group. Dr. Erinjeri accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Erinjeri as offering telehealth.

Dmand AI links 118 papers to Dr. Erinjeri, published from 2013 to 2025. 2016 was the busiest year, with 12. The most frequent topics are Liver Neoplasms, Embolization, Therapeutic and Carcinoma, Hepatocellular. Dr. Erinjeri has published most often in J Vasc Interv Radiol. Dr. Erinjeri's most frequent co-authors are Stephen Barnett Solomon, MD, George I. Getrajdman, MD and Lynn A. Brody, MD.

CMS Open Payments shows 94 general payments to Dr. Erinjeri from 15 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 73% of the total. AstraZeneca Pharmaceuticals LP paid the most, $60,165.

Dr. Erinjeri graduated from Washington University School of Medicine in 2002.